DNAzyme-based Nanotherapeutics Development
DNAzymes are critical for the inactivation of tumor-related genes as they selectively cleave target genes and inhibit corresponding protein expression. Emerging nanotechnologies offer significant promise in overcoming low delivery problems for DNAzymes, providing new hope for their effective use in rare disease treatment. As an innovative company specializing in the development of therapies for rare diseases, our company is dedicated to providing clients with DNAzyme-based nanotherapeutic therapy development services for rare diseases.
DNAzymes and Nanocarriers
DNAzymes have been discovered to possess specific functions, such as degrading target genes, and ligating, or phosphorylating DNA. DNAzymes can cleave target genes, leading to a reduction in protein expression, making them a potential and potent gene-regulation tool, offering a novel gene therapy approach for rare diseases. However, the low delivery and cellular uptake efficiency of DNAzymes has hindered their widespread application in rare diseases.
Fig.1 The synthesis of DNAzyme-based nanosponges. (Qiu, Guo-Hua, et al., 2019)
Nanocarriers of appropriate size can prevent the degradation of DNAzyme and deliver it to tumor cells through enhanced permeability and retention (EPR) effect and active targeting after intravenous administration. A nanocarrier is an effective tool to enhance the stability, catalytic activity, and delivery efficiency of DNA enzymes.
DNAzyme-based Nanotherapeutics
DNAzyme-based nanotherapeutics are capable of effectively delivering DNAzyme to rare disease-affected tissues or tumor microenvironments. During the transport process from the administration site to the body's tissues, DNAzyme can overcome various physiological barriers, including high interstitial pressure in diseased or tumor tissues, abundant disease-associated extracellular matrix, and the risk of degradation by nucleases. Based on the significant advantages of DNAzymes, the latest developments in DNAzyme technology are focused on how to develop intelligent nanoplatforms for the efficient delivery of DNAzymes in cancer and rare disease therapies.
Our Services
With rich experience, our company provides a full range of DNAzyme-based nanotherapeutics development services, which can target the delivery of DNAzyme to rare diseases and treat rare diseases by regulating and repairing DNA. Our customized solutions can meet any of your rare disease gene therapy research needs.
DNAzyme Development
- DNAzyme design
- DNAzyme sequencing
- DNAzyme construction
- DNAzyme optimization
Nanoparticle Development
Our company has been committed to the construction of nanoparticle development platform for many years and can meet your needs for different types of nanoparticles.
Targeted System Development
For specific diseases or pathological processes, DNAzymes with the ability to target specific genes are designed and combined with nanoparticles to achieve precise treatment of rare diseases.
DNAzyme-based Nanotherapeutics Analysis
- Analysis of stability
- Analysis of efficiency and cytotoxicity
- Detection of cellular uptake of nucleic acid-loaded nanoparticles
Why Choose Us?
As an integrated CRO, our company has extensive expertise in DNAzyme-based nanotherapeutics development for rare disease research. Whatever your specific requirements, we will work closely with you to develop a customized solution. We can quickly respond to the changing needs of your rare disease research projects. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
Reference
- Huo, Wendi, et al. "Recent advances of DNAzyme-based nanotherapeutic platform in cancer gene therapy." Biophysics Reports 6 (2020): 256-265.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.